Journal
ARCHIVES OF CLINICAL NEUROPSYCHOLOGY
Volume 28, Issue 4, Pages 320-330Publisher
OXFORD UNIV PRESS
DOI: 10.1093/arclin/act021
Keywords
Cognition; Assessment; Neuropsychological tests; Alzheimers disease; Cognitive tests
Categories
Funding
- AstraZeneca Pharmaceuticals LP
- CSIRO Flagship Collaboration Fund
- Science and Industry Endowment Fund (SIEF)
- Edith Cowan University (ECU)
- Mental Health Research institute (MHRI)
- Alzheimer's Australia (AA)
- National Ageing Research Institute (NARI)
- Austin Health
- CogState Ltd
- Hollywood Private Hospital
- Sir Charles Gardner Hospital
- National Health and Medical Research Council (NHMRC)
- Dementia Collaborative Research Centres program (DCRC)
- McCusker Alzheimer's Research Foundation
Ask authors/readers for more resources
Large prospective studies of Alzheimers disease (AD) have sought to understand the pathological evolution of AD and factors that may influence the rate of disease progression. Estimates of rates of cognitive change are available for 12 or 24 months, but not for shorter time frames (e.g., 3 or 6 months). Most clinical drug trials seeking to reduce or modify AD symptoms have been conducted over 12- or 24-week periods. As such, we aimed to characterize the performance of a group of healthy older adults, adults with amnestic mild cognitive impairment (aMCI), and adults with AD on the CogState battery of tests over short testretest intervals. This study recruited 105 healthy older adults, 48 adults with aMCI, and 42 adults with AD from the Australian Imaging, Biomarkers, and Lifestyle study and administered the CogState battery monthly over 3 months. The CogState battery of tests showed high testretest reliability and stability in all clinical groups when participants were assessed over 3 months. When considered at baseline, the CogState battery of tests was able to detect AD-related cognitive impairment. The data provide important estimates of the reliability, stability, and variability of each cognitive test in healthy older adults, adults with aMCI, and adults with AD. This may potentially be used to inform future estimates of cognitive change in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available